Nkarta Inc

Nkarta is a clinical-stage biotechnology company developing allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. The company's lead product candidate, NKX019, is an allogeneic, cryopreserved immunotherapy that uses NK cells derived from peripheral blood of healthy adult donors, engineered with a humanized CD19-directed chimeric antigen receptor (CAR) and a proprietary membrane-bound form of interleukin-15 (IL-15) for enhanced persistence and activity without exogenous cytokine support. NKX019 is currently being evaluated in two multi-center, open-label, dose-escalation clinical trials (Ntrust-1 and Ntrust-2) across six autoimmune indications: systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, and primary membranous nephropathy. The company's approach leverages the innate immune system to eliminate pathogenic B cells driving the autoimmune response, with on-demand availability and outpatient dosing designed to enable broad patient access in community health settings. Updated Aug 10, 2026